<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053452</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102385</org_study_id>
    <nct_id>NCT04053452</nct_id>
  </id_info>
  <brief_title>Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome</brief_title>
  <official_title>Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if peripheral nerve ultrasound can be used as a
      supplemental tool to diagnose Guillain-Barre syndrome (GBS) in the acute setting and aid in
      prognostication.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to COVID-19 restrictions
  </why_stopped>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The EMG lab physician or technician performing the ultrasound will be blinded to the EMG/NCS results.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Internerve variability of cross-sectional area (CSA) in patients with GBS vs controls at Day 0</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>ROC curve of internerve CSA variability between patients with GBS and controls using ulnar and median nerves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Internerve CSA variability in the diagnosis of patients with GBS vs controls at Day 7</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>ROC curve of internerve CSA variability between patients with GBS and controls using ulnar and median nerves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ulnar nerve CSA variability in patients with GBS vs controls at Day 0</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>ROC curve of intranerve CSA variability between patients with GBS and controls using ulnar nerves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ulnar nerve CSA variability in patients with GBS vs controls at Day 7</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>ROC curve of intranerve CSA variability between patients with GBS and controls using ulnar nerves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median nerve CSA variability in patients with GBS vs controls at Day 0</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>ROC curve of intranerve CSA variability between patients with GBS and controls using ulnar nerves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median nerve CSA variability in patients with GBS vs controls at Day 7</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>ROC curve of intranerve CSA variability between patients with GBS and controls using ulnar nerves</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound in prediction of disability in patients with GBS at Day 0</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Disability is measured by the GBS Disability Score. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound in prediction of disability in patients with GBS at Day 7.</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Disability is measured by the GBS Disability Score. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound in prediction of length of hospital stay in patients with GBS at Day 0</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Length of hospital stay is measured to the nearest day (by chart review). Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound in prediction of length of hospital stay in patients with GBS at Day 7.</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Length of hospital stay is measured to the nearest day (by chart review). Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured on Day 0 in prediction of ambulatory status on discharge in patients with GBS</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Ambulatory status is either (1) ambulatory with or without assistance or (2) non-ambulatory (by chart review). Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured on Day 7 in prediction of ambulatory status on discharge in patients with GBS</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Ambulatory status is either (1) ambulatory with or without assistance or (2) non-ambulatory (by chart review). Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 0 in prediction of severity of respiratory dysfunction in patients with GBS.</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Respiratory dysfunction will be measured by number of days intubated (to the nearest day) by chart review. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 7 in prediction of severity of respiratory dysfunction in patients with GBS.</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Respiratory dysfunction will be measured by number of days intubated (to the nearest day) by chart review. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 0 in prediction of severity of weakness in patients with GBS.</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Weakness will be measured by hand dynamometer. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 0 in prediction of severity of weakness in patients with GBS.</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Weakness will be measured by manual muscle testing using the Medical Research Council (MRC) scale. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 7 in prediction of severity of weakness in patients with GBS.</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Weakness will be measured by hand dynamometer. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 7 in prediction of severity of weakness in patients with GBS.</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Weakness will be measured by manual muscle testing using the Medical Research Council (MRC) scale. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 0 in prediction of autonomic dysfunction in patients with GBS.</measure>
    <time_frame>Within 30 days after symptom onset</time_frame>
    <description>Autonomic dysfunction will be either present or absent by chart review. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of peripheral nerve ultrasound when measured at Day 7 in prediction of autonomic dysfunction in patients with GBS.</measure>
    <time_frame>Approximately 7 days after admission</time_frame>
    <description>Autonomic dysfunction will be either present or absent by chart review. Peripheral nerve ultrasound measures are internerve and intranerve CSA and mean CSA of median nerve, ulnar nerve, vagus nerve, C6 nerve root, and C7 nerve root).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Guillain-Barre Syndrome</condition>
  <arm_group>
    <arm_group_label>GBS Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Peripheral nerve ultrasound</intervention_name>
    <description>Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>GBS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurement of strength</intervention_name>
    <description>Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.</description>
    <arm_group_label>GBS Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For GBS group: Inpatients with acute, progressive weakness and no alternative
             diagnosis, with onset less than 30 days prior to examination.

          -  For control group: Hospitalized patients on the inpatient neurology service who are
             being treated for non-peripheral nerve disorders (e.g. epilepsy, multiple sclerosis,
             or stroke).

          -  For all subjects: 18+ years of age

        Exclusion Criteria:

        - Patients with any history of multifocal motor neuropathy (MMN), prior Guillain-Barre
        syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), or hereditary
        neuropathy (e.g. Charcot-Marie-Tooth)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Hobson-Webb, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

